Prevention of Atrial Fibrillation Recurrence With Corticosteroids After Radiofrequency Catheter Ablation: A Randomized Controlled Trial
Koyama T, Tada H, Sekiguchi Y, et al.
J Am Coll Cardiol 2010;56:1463-1472.
Study Question: Does steroid therapy reduce the probability of recurrent atrial fibrillation (AF) after radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation (PAF)?
Cardiorespiratory Fitness Is Related to the Risk of Sudden Cardiac Death: A Population-Based Follow-Up Study
Laukkanen JA, M?kikallio TH, Rauramaa R, Kiviniemi V, Ronkainen K, Kurl S.
J Am Coll Cardiol 2010;56:1476-1483.
Study Question: Does cardiopulmonary fitness predict one’s risk for sudden cardiac death (SCD)?
Improvements in Symptoms and Quality of Life in Patients With Paroxysmal Atrial Fibrillation Treated With Radiofrequency Catheter Ablation Versus Antiarrhythmic Drugs
Reynolds MR, Walczak J, White SA, et al.
Circ Cardiovasc Qual Outcomes 2010;Oct 12:[Epub ahead of print].
Study Question: Does radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation (AF) improve quality of life (QOL) to a greater extent than antiarrhythmic drug therapy?
Heart Failure Reversal by Ventricular Unloading in Patients With Chronic Cardiomyopathy: Criteria for Weaning From Ventricular Assist Devices
Dandel M, Weng Y, Siniawski H, et al.
Eur Heart J 2010;Oct 7:[Epub ahead of print].
Study Question: What are correlates of long-term success following ventricular assist device (VAD) wean for myocardial recovery?
Arteriotomy Closure Devices for Cardiovascular Procedures: A Scientific Statement From the American Heart Association
Patel MR, Jneid H, Derdeyn CP, et al.
Circulation 2010;Oct 4:[Epub ahead of print].
Perspective: The following are 10 points to remember about this scientific statement.
Follow-up After Pulmonary Valve Replacement in Adults With Tetralogy of Fallot: Association Between QRS Duration and Outcome
Scherptong RW, Hazekamp MG, Mulder BJ, et al.
J Am Coll Cardiol 2010;56:1486-1492.
Study Question: Is QRS duration before and after pulmonary valve replacement (PVR) related to long-term outcomes in patients with tetralogy of Fallot (TOF)?
Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity
Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ.
JACC Cardiovasc Interv 2010;3:1001-1007.
Study Question: Does doubling the dose of clopidogrel from 75-150 mg/day reduce platelet reactivity in patients with high on-treatment platelet reactivity (OTR)? Does this response differ based on CYP2C19 status?
Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients
Rosenberg S, Elashoff MR, Beineke P, et al., on behalf of the PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators.
Ann Intern Med 2010;153:425-434.
Study Question: What is the predictive ability of a 23-gene expression-based classification test for diagnosis of obstructive coronary artery disease (CAD) in nondiabetic patients?
Enhanced External Counterpulsation Improves Peripheral Artery Flow-Mediated Dilation in Patients With Chronic Angina. A Randomized Sham-Controlled Study
Braith RW, Conti CR, Nichols WW, et al.
Circulation 2010;122:1612-1620.
Study Question: What are the mechanisms responsible for clinical and anti-ischemic benefits of enhanced external counterpulsation (EECP)?
Association Between Visceral Adipose Tissue Area and Coronary Plaque Morphology Assessed by CT Angiography
Ohashi N, Yamamoto H, Horiguchi J, et al.
J Am Coll Cardiol Img 2010;3:908-917.
Study Question: Is visceral adipose tissue area associated with coronary plaque morphology?
Magnetic Resonance Imaging and Troponin Elevation Following Percutaneous Coronary Intervention: New Insights Into Myocyte Necrosis and Scar Formation
Schoenhagen P, White HD.
J Am Coll Cardiol Intv 2010;3:959-962.
Perspective: The universal definition of myocardial infarction (MI) designates biomarker increase (with troponin preferred) from a normal baseline to a level 3 times the 99th percentile as percutaneous coronary intervention (PCI)-related MI (Type 4a).
|